My research is primarily focused on defining the role of SHIP1 in immunity, obesity, stem cell biology and cancer. This research has revealed that SHIP1 is at the nexus of signaling pathways that regulate: (1) hematopoietic and mesenchymal stem cell homeostasis, (2) terminal differentiation of myeloid cells, (3) acute BM graft rejection, (4) survival of T cells in the small intestine and (5) survival of hematologic cancer cells. More recently we developed SHIP1 and pan-SHIP1/2 inhibitors and showed they can expand stem cells in vivo, reverse obesity, eradicate certain cancers and boost tumor immunity. We are also attempting to better understand what LRBA does in immune cells. LRBA is a scaffold protein that coordinates intracellular vesicle trafficking with receptor signaling.